Growth hormone treatment of short Chinese children with beta-thalassaemia major without GH deficiency.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

Despite regular transfusion and desferrioxamine treatment, growth failure is commonly seen in adolescent children with beta-thalassaemia major.

The growth failure has been thought to be due to GH resistance rather than GH deficiency.

The researchers investigated the effect of GH on short non-GH deficient children with beta-thalassaemia.

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

All children had peak GH response > 15mlU/l to insulin induced hypoglycaemia and normal thyroid function and adrenal reserve.

Anthropometric measurements were performed every 3 months.

How the Study Was Run

Blood count, renal and liver function tests, fasting blood glucose, IGF-I and fructosamine levels were assessed at entry and every 3 months during treatment.

Fasting insulin was measured before and after 3 and 12 months of GH treatment.

What Was Measured

PubMed files the paper under topics including Body Height, Growth Disorders, Growth Hormone, Insulin-Like Growth Factor I, Recombinant Proteins and beta-Thalassemia.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1995 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.